AC Immune is a clinical stage biopharmaceutical company leveraging Co.'s two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Co. designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. Co.'s technology platforms create antibodies, small molecules, and vaccines to address a broad spectrum of neurodegenerative indications. Co. offers its therapies to address Alzheimer disease and neurodegenerative diseases, such as Parkinson's, Down syndrome, and glaucoma. We show 3 historical shares outstanding datapoints in our coverage of ACIU's shares outstanding history.
Understanding the changing numbers of ACIU shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACIU versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACIU by allowing them to research ACIU shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
